An expert would summarize that bladder cancer management is evolving from traditional radical surgery toward more personalized, less invasive approaches—highlighting promising therapies like Tara-002 ...

The expanded labeling would enable the use of flibanserin to treat hypoactive sexual desire disorder in postmenopausal women.

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

Panelists discuss how the treatment paradigm for androgen deprivation therapy is evolving from traditional injectable GnRH agonists to include oral GnRH antagonists like relugolix, which offer more ...

In this interview, Daniel D. Joyce, MD, MS, assistant professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee, discusses the economic and clinical considerations of using ...

One consideration is the setting in which the procedure is performed. The FDA recently expanded the label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, In this interview, ...

Millennial urologists appear to have developed strong opinions on health policy as reflected by their recent social media activity, observes urologist Alan L. Kaplan, MD.

Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...

Panelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and ...

Key Takeaways The Co-PSMA trial compares 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT for detecting prostate cancer recurrence post-radical prostatectomy. 64Cu-SAR-bisPSMA has received FDA fast track ...

The FDA and the French National Agency for the Safety of Medicines and Health Products (ANSM) have granted an investigational device exemption (IDE) clearance to a pivotal trial of the UroActive smart ...

Key Takeaways Hamlet BioPharma is preparing to initiate a phase 3 trial of Alpha1H for NMIBC, following a successful FDA meeting. Alpha1H received fast track designation, allowing for accelerated ...